Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model.

Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. Abstract Text:

M F Sciadini,K D Johnson,

A study was performed in dogs to evaluate the dose-response characteristics and effectiveness of recombinant human bone morphogenetic protein-2 with a collagen sponge carrier in a segmental defect model. Twenty-seven dogs underwent bilateral radial osteotomies with creation of a 2.5-cm diaphyseal defect. All received autogenous cancellous bone graft in one defect and a collagen implant in the other. These implants contained recombinant human bone morphogenetic protein-2 at the following doses: group 1 at 0 microg (three dogs, 0 microg/ml total implant volume), group 2 at 150 microg (three dogs, 50 microg/ml), group 3 at 600 ,g (three dogs, 200 microg/ml), group 4 at 2,400 microg (three dogs, 800 microg/ml), group 5 at 0 microg (five dogs, 0 microg/ml), group 6 at 150 microg (five dogs, 200 microg/ml), and group 7 at 600 microg (five dogs, 50 microg/ml). The defects were stabilized with external fixators. The dogs in groups 1-4 were killed at 12 weeks postoperatively, and those in groups 5-7 were killed at 24 weeks postoperatively except for one dog in group 7, which was killed at 48 weeks. Evaluation included monthly radiographs, biomechanical testing, and nondemineralized histology. All 27 radii with autogenous cancellous bone graft and all 19 implants treated with recombinant human bone morphogenetic protein-2 achieved radiographic and histologic union and gross stability. The eight radii treated with collagen carrier alone went on to radiographic and histologic nonunion and were grossly unstable at death. A dose-dependent occurrence of cyst-like bone voids was noted radiographically and histologically. Biomechanical performance tended to be better at the lowest dose studied at 12 weeks, and all three doses performed better than the placebo (p < 0.05) at 12 and 24 weeks. By 24 weeks, radiolucent areas corresponding to histologic bone voids persisted radiographically, although there was evidence of early bone remodeling. This remodeling progressed to 48 weeks in the single animal followed to this time point, although bone voids remained. These radiologic findings were confirmed histologically. Recombinant human bone morphogenetic protein-2 in a collagen sponge carrier has significant osteoinductive activity in this canine segmental defect model. A dose-response relationship is evident, with heterotopic bone and cyst-like void formation at higher doses and a minimum effective dose of 0-150 microg. At 12 and 24 weeks postoperatively, biomechanical parameters achieved by defects treated with recombinant human bone morphogenetic protein-2 were comparable with those of autograft controls and were significantly stronger than those of the placebo (p < 0.05).

Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. Publishing Authors By Initials

MF Sciadini,KD Johnson,

For similar peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research abstracts see: peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research

PUBMED ID PMID:

MEDLINE DATE:

Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of orthopaedic research : official publica

VOLUME: 18

Page Numbers: 289-302

Journal Abbreviation: J. Orthop. Res.

ISSN: 0736-0266

DAY: 19

MONTH: Mar

YEAR: 2000

Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8404726

Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. Keywords Mesh Terms:

KEYWORDS: Transforming Growth Factor beta

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. Information

Substance Name: recombinant human bone morphogenetic pro

Registry Number: 0

Grant and Affiliation Information for Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model.

AFFILIATION: Department of Orthopaedics and Rehabilitation, Vanderbilt University, Nashville, Tennessee, USA.

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Orthop Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model Related Publications

• A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non Small-Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial.
• A method for one-step freezing of mouse embryos.
• Active immunization of boars against gonadotrop in releasing hormone. I. Effects on reproductive parameters.
• Active immunization of boars against gonadotropin releasing hormone. II. Effects on libido and response to testosterone propionate.
• An eight-position capillary sample spinning stage for the diffractometer at BL20B at the Photon Factory.
• An extract of the mushroom Agaricus blazei Murill protects against lethal septicemia in a mouse model of fecal peritonitis.
• Cardiac hypertrophy in infancy.
• Effect of castration on plasma luteinizing hormone in postpubertal boars.
• Effects of postparturient uterine lavage on uterine involution in the mare.
• Effects of pretreatment with adrenocorticotropin on endocrine and behavioral responses of bulls to sexual activity.
• Effects of zeranol upon bovine testicular function.
• Embryo transfer tests for bovine syndactyly.
• Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model.
• Factors related to successful sperm microinjection of hamster eggs: The effect of sperm species, technical experience, needle dimensions, and incubation medium on egg viability and sperm decondensation following microinjection.
• Leading from the edge, and toward the light: some lessons on leadership from the business world.
• Progesterone profiles in postpartum Holstein dairy cows as an aid in the study of retained fetal membranes, pyometra and anestrus.
• Quantum-dot-based nanosensor for RRE IIB RNA-Rev peptide interaction assay.
• Relationship between serum luteinizing hormone and estradiol in prepubertal boars.
• Scrotal circumference does not accurately predict degree of germinal epithelial loss or semen quality in yearling Hereford and Simmental bulls.
• Single site electronic spectroscopy of free base octaethylporphyrin, octaethychlorin and their diacids in n-octane at 298K and 7K.
• Single site electronic spectroscopy of magnesium isobacteriochlorin in n-octane matrixes at 7 K.
• Skin and subcutaneous tissue in rhinoplasty.
• Techniques of Online Citation Verification in NLM Databases.
• Temporal relationships among peripheral blood concentrations of corticosteroids, luteinizing hormone and testosterone in bulls.
• Testing the adaptive value of circadian systems.
• The effect of co-treatment with recombinant bovine somatotrophin on plasma progesterone concentration and number of embryos collected from superovulated Holstein heifers.
• The effect of prostaglandin administration to Holstein-Friesian cows at Day 26 postpartum on clinical findings, and histological and bacteriological results of endometrial biopsies at Day 40.
• The recovery of ureaplasmas from bovine embryos following in vitro exposure and ten washes.
• The use of real-time ultrasound rectally for early pregnancy diagnosis in sheep.
• Variation in testosterone production among boards and its relationship to sexual interest and breeding performance.